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Pulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because of its
nonspeciﬁc signs and symptoms. PE is also an important potential risk of osimertinib treatment, how-
ever, clinical courses regarding retreatment after osimertinib-induced acute pulmonary embolism
remain unclear. We described a 77-year-old woman with postoperative recurrent lung adenocarcinoma
who developed osimertinib-induced acute PE. She received apixaban and was later successfully retreated
with osimertinib. This case suggests that retreatment with osimertinib after osimertinib-induced acute
PE may be a treatment option when alternative therapeutic options are limited.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Venous thromboembolism (VTE), comprising deep vein throm-
bosis (DVT) and pulmonary embolism (PE), is a major cause of death
in cancer patients. Osimertinib has been approved for the treatment
of epidermal growth factor receptor (EGFR) T790M mutation-
positive non-small cell lung cancer that are resistant to ﬁrst- or
second-generation EGFR tyrosine kinase inhibitors. However, little
is known about VTE induced by osimertinib. Here, we report a case
of successful retreatment with osimertinib after osimertinib-
induced acute PE in a patient with lung adenocarcinoma.
2. Case
A 77-year-old non-smoking woman with postoperative recur-
rent lung adenocarcinoma harboring an EGFR L858R mutation was
found to have disease progression after receiving geﬁtinibceptor; ILD, interstitial lung
alignancy, Osaka Prefectural
-7-1 Habikino, Habikino City,
royama).
Ltd. This is an open access article utreatment for 2 years followed by afatinib treatment for 3 months.
A chest computed tomography (CT) and head magnetic resonance
imaging (MRI) scan demonstrated that recurrence was conﬁned to
multiple pulmonary metastases and the brain metastases in the
right frontal lobe. To evaluate resistance mechanisms, broncho-
scopic rebiopsy was performed, for which the cobas® EGFR Muta-
tion Test v2 (Roche Molecular Systems) was used, and results
showed the emergence of an EGFR T790M mutation. Therefore,
osimertinib (80 mg once daily) was started. After 16 days of osi-
mertinib treatment, she developed acute shortness of breath on
exertion. A CT scan showed a very small area of ground-glass
opacity in the right lung (Fig. 1). It was likely that osimertinib-
induced interstitial lung disease (ILD) developed; therefore, osi-
mertinibwas discontinued. After one week of careful observation, a
CT scan showed disappearance of the shadow in the apex of the
right lung and no new ﬁndings. However, shortness of breath on
exertion persisted. Although she had no chest pain, leg pain, he-
modynamic instability, and abnormalities on echocardiography, PE
was considered. The D-dimer level was as high as 37.7 mg/mL, and a
subsequent contrast CT scan showed a thrombus in both pulmo-
nary arteries (Fig. 2A) and the vein of the lower extremities. She
was immediately given apixaban, a direct inhibitor of factor Xa.
After onemonth, dyspnea completely disappeared and the D-dimer
values normalized, however, neurological deterioration occurrednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography scan of the right lung. A very small area of ground-glass
opacity is observed in the apex of the right lung after 16 days of osimertinib treatment.
Fig. 2. Contrast computed tomography (CT) scan of the pulmonary arteries. A
thrombus is shown in both pulmonary arteries (A). A contrast CT scan 2 months from
starting anticoagulant treatment showing no evidence of a thrombus (B).
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receiving full informed consent for the risk of recurrent VTE,
because no alternative treatment was available. One month later, a
contrast CT and MRI scan showed disappearance of the thrombus
(Fig. 2B) and partial remission of multiple pulmonary and brain
metastases. As a result, her neurological symptoms improved.
Currently, she is being treated with osimertinib and apixaban for 4
months without major adverse events.
3. Discussion
VTE is a disease that includes DVT and PE, and DVT is the cause
of PE in more than 90% of patients. Cancer and chemotherapy are
the main risk factors for VTE, and VTE is considered an important
potential risk of osimertinib treatment, based on the ﬁnding that
the most common Grade 3-4 adverse reaction in the AURA study
was pulmonary embolism (2.4%, 6/253) [1]. Cancer-associatedthrombosis is characterized by multiple pathophysiological mech-
anisms, and cancer biology and thrombus formation are inter-
connected; however, the precise mechanism of VTE induced by
osimertinib remains unknown [2]. PE can be life-threatening, and it
is challenging to diagnose because of its nonspeciﬁc signs and
symptoms. Furthermore, PE is largely undiagnosed because clinical
suspicion is not raised in most instances. In fact, the patient pre-
sented in this case had no obvious signs of VTE and was considered
low probability for VTE according to the Wells criteria [3]. There-
fore, clinical suspicion is important to make an early diagnosis of
VTE. A recent report has shown that in patients diagnosed with
acute symptomatic PE, concomitant DVT was signiﬁcantly associ-
ated with increased 30-day mortality [4]. The diagnosis of PE
should be suspected in cancer patients with respiratory symptoms
unexplained by an alternative diagnosis. It is difﬁcult to differen-
tiate between tumor embolism and thromboembolism. Pulmonary
wedge aspiration cytology has been reported to be useful in the
diagnosis of pulmonary tumor embolism [5,6]. In our case, we think
that pulmonary embolismwas caused by the thrombus induced by
osimertinib and not from the metastatic lung cancer, because the
thrombus immediately disappeared only after anticoagulation
therapy. The tiny shadow that was found via CT on day 16 of osi-
mertinib treatment was thought to result from VTE. Ground-glass
opacity of the lung is sometimes seen in patients with acute PE,
and this may be explained by decreased blood ﬂow and broncho-
constriction [7].
According to the American Society of Clinical Oncology guide-
line for VTE prevention, hospitalized patients with cancer may be
considered for pharmacologic thromboprophylaxis in the absence
of bleeding or other contraindications [8]. In practice, adherence to
this guideline seems to still be low because of the additional
bleeding risk associated with anticoagulant treatment and inter-
action between drugs. Previous studies have shown that prophy-
laxis for VTE is rarely used in patients undergoing treatment for
cancer [9,10].
To our knowledge, this is the ﬁrst report of successful retreat-
ment with osimertinib after the development of osimertinib-
induced VTE. Considering that VTE is associated with a high mor-
tality, physicians should be aware of the possibility of such a severe
adverse event as well as ILD during treatmentwith osimertinib, and
retreatment with osimertinib must be carefully chosen based on
the balance of a patient's risk and beneﬁt. This case suggests that
retreatment with osimertinib after osimertinib-induced PE may be
a treatment option when alternative therapeutic options are
limited.
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